Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

As Korea Steps Up Drive To Attract Global Clinical Trials, American CRO Opens Outpost In Seoul

This article was originally published in PharmAsia News

Executive Summary

SEOUL - PRA International, a clinical research organization headquartered in Raleigh, N.C., recently opened its first office in Seoul as part of an expansion across Asia

You may also be interested in...



Seoul National University Hospital Partners With Quintiles On Clinical Trials

SEOUL - Seoul National University Hospital, which is at the forefront of the government's drive to make South Korea a hub for global clinical trials, has signed a strategic alliance agreement to take part in Quintiles' Prime Site program

Seoul National University Hospital Partners With Quintiles On Clinical Trials

SEOUL - Seoul National University Hospital, which is at the forefront of the government's drive to make South Korea a hub for global clinical trials, has signed a strategic alliance agreement to take part in Quintiles' Prime Site program

More Talks Needed With China and Japan For Cooperation In Sharing Clinical Data - Korea FDA Official

SEOUL - Although drug regulatory officials from South Korea, Japan and China met in Beijing for two days from Dec. 17 in their second tri-party meeting, they failed to report "noticeable progress" in their pursuit of an integrated clinical trial data-sharing program and mutual acceptance of their rules and guidelines, according to Korea FDA

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072293

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel